GO:0070330 aromatase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070330 (aromatase activity) is the catalytic conversion of androgens (testosterone, androstenedione) into estrogens (17beta-estradiol, estrone) by the CYP19A1 enzyme.
• Aromatase is a cytochrome P450 enzyme that requires NADPH-hemoprotein reductase and molecular oxygen for its three-step catalytic cycle.
• Aromatase activity is critical for reproductive physiology, bone homeostasis, and brain function, and its dysregulation is implicated in breast cancer, polycystic ovary syndrome, and dementia.
• CYP19A1 expression and activity are regulated by tissue-specific promoters, hormones (FSH, androgens), and post-translational modifications such as acetylation.
• Research methods for aromatase activity include live-cell fluorometric assays, radiolabeled substrate conversion, and molecular docking studies.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of CYP19A1 function in health and disease.
Description
Aromatase activity (GO:0070330) is a molecular function that catalyzes the biosynthesis of estrogens from androgens. This activity is essential for normal reproductive development, bone health, and neuroendocrine regulation. The enzyme responsible, CYP19A1, is a member of the cytochrome P450 superfamily and is expressed in a tissue-specific manner in gonads, adipose tissue, brain, and bone. Dysregulated aromatase activity is associated with breast cancer, polycystic ovary syndrome (PCOS), and neurodegenerative conditions. Understanding the mechanisms, regulation, and research tools for aromatase activity is therefore of broad biomedical importance.
aromatase activity At A Glance
| GO ID | GO:0070330 |
|---|---|
| GO term | aromatase activity |
| Ontology | molecular_function |
| Synonym | estrogen synthetase activity |
| Major function | Catalyzes the aromatization of androgens to estrogens, specifically the conversion of testosterone to 17beta-estradiol and androstenedione to estrone. |
| Cofactors | Requires NADPH-hemoprotein reductase and molecular oxygen. |
| Substrates | Testosterone, androst-4-ene-3,17-dione (androstenedione). |
| Products | 17beta-estradiol, estrone, formate, water, and oxidized NADPH-hemoprotein reductase. |
| Enzyme | CYP19A1 (aromatase), a cytochrome P450 enzyme. |
What Is GO:0070330?
According to the Gene Ontology, aromatase activity (GO:0070330) is defined as the catalysis of the reaction: 3 O2 + 3 reduced [NADPH--hemoprotein reductase] + testosterone = 17beta-estradiol + formate + 4 H+ + 4 H2O + 3 oxidized [NADPH--hemoprotein reductase]. It also converts androst-4-ene-3,17-dione into estrone. In simpler terms, it is the enzyme activity that turns male sex hormones (androgens) into female sex hormones (estrogens).
Why Is aromatase activity Important in Cell Biology?
Aromatase activity is a central node in steroid hormone biosynthesis, controlling the balance between androgens and estrogens. This balance is critical for reproductive function, bone density, lipid metabolism, and brain health. Pharmacological inhibition of aromatase is a mainstay therapy for estrogen receptor-positive breast cancer, and altered aromatase activity in tissues is a potential biomarker for disease progression. Moreover, aromatase activity in the brain influences sexual behavior and may protect against neurodegeneration.
• Essential for estrogen biosynthesis in gonads, adipose tissue, brain, and bone.
• Regulates reproductive cycles and folliculogenesis; interacts with FSH and anti-Müllerian hormone.
• Influences bone mineral density and skeletal homeostasis.
• Modulates sexual behavior and neuroendocrine circuits in the brain.
• Dysregulated in breast cancer, where local estrogen production promotes tumor growth.
• Implicated in polycystic ovary syndrome (PCOS) through androgen excess.
• Linked to presenile dementia via autophagic degradation of CYP19A1 in female mice.
• Target for aromatase inhibitors used in breast cancer therapy.
• Post-translational modifications (acetylation) regulate aromatase activity.
• A key enzyme for studying steroid metabolism and endocrine disruption.
What Happens During aromatase activity?
Substrate binding and initial hydroxylation
In simple terms: The enzyme grabs testosterone and adds an oxygen atom to it.
Aromatase (CYP19A1) binds its substrate, testosterone or androstenedione, in the active site. The heme iron of the cytochrome P450 domain coordinates molecular oxygen, and with electrons from NADPH-hemoprotein reductase, it performs the first hydroxylation at the C19 methyl group.
Second hydroxylation and formate release
In simple terms: A second oxygen is added, leading to the removal of a carbon atom as formate.
The initial hydroxylated intermediate undergoes a second hydroxylation, resulting in the formation of a gem-diol that collapses to release formate. This step is unique to aromatase among P450 enzymes and is essential for the aromatization of the A-ring.
Aromatization and estrogen production
In simple terms: The A-ring of the steroid becomes aromatic, producing estrogen.
The final step involves the aromatization of the steroid A-ring, converting the androgenic structure into an estrogenic one. For testosterone, the product is 17beta-estradiol; for androstenedione, the product is estrone.
Tissue-specific regulation of aromatase activity
In simple terms: Different tissues control how much aromatase is made and how active it is.
Aromatase activity is regulated by tissue-specific promoters that drive CYP19A1 expression in gonads, adipose tissue, brain, and bone. Hormones such as FSH and androgens, as well as anti-Müllerian hormone, modulate aromatase activity during folliculogenesis. In bone-derived cells, MAPK signaling may regulate aromatase activity.
Post-translational modification and degradation
In simple terms: Chemical tags on the enzyme can change its activity or cause its destruction.
Acetylation of aromatase affects its activity, and sirtuin inhibition alters acetylation patterns, leading to changes in enzyme function. In the brain, autophagic degradation of CYP19A1 can reduce aromatase activity, contributing to dementia-like pathology in female mice.
Key Genes Involved in GO:0070330 aromatase activity
The following genes and proteins are directly involved in aromatase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP19A1 | Encodes aromatase, the enzyme catalyzing estrogen synthesis | Target for breast cancer therapy; studied in PCOS and bone metabolism |
| NADPH-hemoprotein reductase (POR) | Provides electrons to CYP19A1 for catalysis | Essential cofactor for aromatase activity assays |
| FSHR | Receptor for FSH, regulates aromatase expression in granulosa cells | Implicated in folliculogenesis and PCOS |
| AMH | Anti-Müllerian hormone, modulates aromatase activity in follicles | Biomarker for ovarian reserve and PCOS |
| ESR1 | Estrogen receptor alpha, mediates estrogen signaling | Breast cancer and endocrine resistance |
| ESR2 | Estrogen receptor beta, modulates estrogen action | Brain and bone physiology |
| AR | Androgen receptor, feedback regulation of aromatase | PCOS and androgen excess |
| MAPK1/3 | MAPK signaling pathway, may regulate aromatase in bone | Bone homeostasis |
| SIRT1 | Deacetylase, affects aromatase acetylation and activity | Cancer metabolism and aging |
| TPP2 | Tripeptidyl peptidase II, involved in calcium/lipid homeostasis and CYP19A1 stability | Neurodegeneration and dementia |
| CYP17A1 | Produces androgen precursors for aromatase | Steroidogenesis |
| HSD17B1 | Converts estrone to estradiol | Breast cancer and endometriosis |
| STS | Steroid sulfatase, regulates estrogen availability | Breast cancer |
| NR5A1 | Transcription factor regulating CYP19A1 expression | Gonadal development |
| FOXL2 | Transcription factor in granulosa cells, regulates aromatase | Ovarian function |
| CREB1 | Transcription factor activated by FSH, induces CYP19A1 | Folliculogenesis |
| STAT3 | Transcription factor, modulates aromatase in cancer | Breast cancer |
| TNF | Inflammatory cytokine, inhibits aromatase in some tissues | Breast cancer and inflammation |
How Is aromatase activity Regulated?
Aromatase activity is regulated at multiple levels. Transcriptionally, CYP19A1 uses tissue-specific promoters that respond to hormones such as FSH, androgens, and anti-Müllerian hormone during folliculogenesis. In bone-derived cells, MAPK signaling may modulate aromatase activity. Post-translational modifications, particularly acetylation, alter enzyme activity; inhibition of sirtuins changes acetylation patterns and aromatase activity. In the brain, autophagic degradation of CYP19A1 reduces aromatase activity, and this process is linked to calcium/lipid dyshomeostasis.
aromatase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP19A1 | Breast cancer, PCOS, bone loss | Knockout or point-mutation in MCF-7 and granulosa cell lines |
| TPP2 | Presenile dementia | TPP2 knockout mice, brain-specific CYP19A1 overexpression |
| FSHR | PCOS, infertility | FSHR knockout or knock-in in ovarian cell models |
| ESR1 | Breast cancer, endocrine resistance | ESR1 mutant knock-in in breast cancer cells |
| SIRT1 | Cancer, aging | SIRT1 knockout or overexpression in cancer cell lines |
Breast cancer
Local aromatase activity in breast tissue contributes to estrogen production, which drives hormone receptor-positive breast cancer. Altered aromatase activity in breast cancer tissues may serve as a decision-support biomarker for clinicians. Aromatase inhibitors are used therapeutically, and acetylation of aromatase affects its activity and response to sirtuin inhibition.
Polycystic ovary syndrome (PCOS)
In PCOS, dysregulated interactions between androgens, FSH, anti-Müllerian hormone, and estradiol during folliculogenesis lead to ovulatory dysfunction. Aromatase activity is a key node in this network, as it converts androgens to estrogens in granulosa cells.
Neurodegeneration and dementia
In female mice, depletion of tripeptidyl peptidase II causes presenile dementia through calcium/lipid dyshomeostasis-induced autophagic degradation of CYP19A1, reducing aromatase activity in the brain. This suggests that brain aromatase activity is neuroprotective.
Bone metabolism
Aromatase activity in bone-derived cells is important for maintaining bone mineral density. Regulation of aromatase by MAPK signaling may influence bone homeostasis, and aromatase deficiency leads to bone loss.
From aromatase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CYP19A1 affect estrogen production? | CYP19A1 knockout cell line (e.g., MCF-7 or KGN) |
| How does a specific CYP19A1 mutation alter catalytic activity? | Point-mutation knock-in of CYP19A1 in HEK293T cells |
| Can we tag endogenous aromatase for live-cell imaging? | Knock-in of fluorescent tag (e.g., GFP) at CYP19A1 locus |
| What is the effect of aromatase overexpression in bone cells? | Overexpression of CYP19A1 in osteoblast-like cells |
| How does TPP2 depletion affect brain aromatase? | TPP2 knockout mice with brain-specific CYP19A1 overexpression |
| Does SIRT1 inhibition change aromatase acetylation? | SIRT1 knockout or overexpression in breast cancer cells |
How to Study the aromatase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorometric live-cell assay | Real-time aromatase activity | High-throughput inhibitor screening |
| Radiolabeled substrate conversion | Enzymatic conversion of androgens to estrogens | Kinetic studies |
| Molecular docking | Binding affinity to CYP19A1 | Virtual screening of compounds |
| qPCR/Western blot | CYP19A1 expression levels | Tissue-specific regulation |
| Immunohistochemistry | Localization of aromatase in tissues | Breast cancer biomarker |
| Acetylation assays | Post-translational modification of aromatase | Sirtuin regulation |
| Autophagy flux assays | Degradation of CYP19A1 | Neurodegeneration models |
| MAPK activity assays | Signaling pathways regulating aromatase | Bone cell studies |
Live-cell fluorometric assays
A fluorometric CYP19A1 activity assay in live cells allows real-time measurement of aromatase activity using specific substrates that become fluorescent upon conversion. This method is suitable for high-throughput screening of aromatase inhibitors.
In vitro cytotoxicity and inhibitory activity assays
Flavonoids and other compounds can be tested for aromatase inhibitory activity using in vitro assays, combined with molecular docking and ADME predictions to identify potential therapeutics.
Molecular docking and in silico prediction
Computational docking of compounds into the CYP19A1 active site helps predict binding affinity and inhibitory potential, guiding experimental validation.
Tissue-specific activity measurement
Aromatase activity in breast cancer tissues can be measured to assess local estrogen production, providing potential decision support for clinicians.
How CRISPR Can Be Used to Study GO:0070330 aromatase activity
Knockout
CRISPR-Cas9 knockout of CYP19A1 eliminates aromatase activity, enabling studies of estrogen deprivation in breast cancer cells, granulosa cells, and bone-derived cells. This model is useful for validating the role of local estrogen production in disease.
Point Mutation
Introducing specific point mutations in CYP19A1 via CRISPR base editing or homology-directed repair allows structure-function analysis of the catalytic site, including residues involved in substrate binding and heme coordination.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags at the endogenous CYP19A1 locus enables live-cell imaging and proteomic analysis of aromatase in its native context.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of CYP19A1 can model aromatase excess, as seen in some breast cancers and bone disorders, to study downstream estrogenic effects.
How EDITGENE Supports aromatase activity Research
Researchers studying aromatase activity-related genes often need to determine whether a candidate gene is causally involved in estrogen biosynthesis or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to create precise cellular and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for aromatase activity research.
Frequently Asked Questions About aromatase activity
What is aromatase activity?
Aromatase activity (GO:0070330) is the enzymatic conversion of androgens such as testosterone and androstenedione into estrogens like 17beta-estradiol and estrone, catalyzed by the CYP19A1 enzyme.
What genes are involved in aromatase activity?
The primary gene is CYP19A1, which encodes the aromatase enzyme. Other genes such as FSHR, AMH, ESR1, and SIRT1 regulate its expression or activity.
What is the GO ID for aromatase activity?
The Gene Ontology ID for aromatase activity is GO:0070330.
How is aromatase activity measured?
Aromatase activity can be measured using live-cell fluorometric assays, radiolabeled substrate conversion, or molecular docking studies.
What diseases are associated with altered aromatase activity?
Altered aromatase activity is linked to breast cancer, polycystic ovary syndrome (PCOS), bone loss, and presenile dementia.
What is the role of CYP19A1 in breast cancer?
CYP19A1 produces local estrogens that promote hormone receptor-positive breast cancer growth, making it a target for aromatase inhibitors.
How does aromatase activity affect the brain?
Brain aromatase activity influences sexual behavior and may be neuroprotective; its degradation is associated with dementia in female mice.
Can aromatase activity be regulated by post-translational modifications?
Yes, acetylation of aromatase affects its activity, and sirtuin inhibition alters acetylation patterns.
What are the substrates of aromatase?
The substrates are testosterone and androst-4-ene-3,17-dione (androstenedione).
What cofactors are required for aromatase activity?
Aromatase requires NADPH-hemoprotein reductase and molecular oxygen for catalysis.
Conclusion
Aromatase activity (GO:0070330) is a fundamental molecular function that governs estrogen biosynthesis and impacts reproductive, skeletal, and neurological health. Its dysregulation is implicated in major diseases such as breast cancer, PCOS, and dementia. Understanding its mechanisms and regulation through CRISPR-based models and biochemical assays offers promising avenues for therapeutic development. EDITGENE provides the tools and expertise to accelerate this research.
References
- 1. Brooks DC et al.. 2020. Brain Aromatase and the Regulation of Sexual Activity in Male Mice.. Endocrinology 161(10) PMID: 32910181
- 2. Molehin D et al.. 2018. Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition.. Mol Cancer Res 16(10):1530-1542 PMID: 29921733
- 3. Shah U et al.. 2022. In Vitro Cytotoxicity and Aromatase Inhibitory Activity of Flavonoids: Synthesis, Molecular Docking and In silico ADME Prediction.. Anticancer Agents Med Chem 22(7):1370-1385 PMID: 34455966
- 4. Heidary DK et al.. 2021. A Fluorometric CYP19A1 (Aromatase) Activity Assay in Live Cells.. ChemMedChem 16(18):2845-2850 PMID: 34224206
- 5. Dewailly D et al.. 2016. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.. Hum Reprod Update 22(6):709-724 PMID: 27566840
- 6. Tuzuner MB et al.. 2021. Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians.. Exp Mol Pathol 118:104574 PMID: 33197426
- 7. Zhao J et al.. 2024. Tripeptidyl peptidase II coordinates the homeostasis of calcium and lipids in the central nervous system and its depletion causes presenile dementia in female mice through calcium/lipid dyshomeostasis-induced autophagic degradation of CYP19A1.. Theranostics 14(4):1390-1429 PMID: 38389851
- 8. Shozu M et al.. 2001. Regulation of aromatase activity in bone-derived cells: possible role of mitogen-activated protein kinase.. J Steroid Biochem Mol Biol 79(1-5):61-5 PMID: 11850208
